Rezultati pretraživanja
  1. prije 50 minuta
    Odgovor korisniku/ci

    What's the bull now that data looks poor?

    1 reply
  2. prije 1 sat

    Sold out of +200%, don't get many of these in such a short period of time.

    2 korisnika označavaju da im se sviđa
  3. prije 6 sati

    was analyzed by 7. The buy percentage consensus is at 97. So analysts seem to be very confident about .

  4. prije 9 sati

    Forty Seven Earns Buy Rating from Guggenheim

  5. prije 16 sati

    How the heck did and stay up after clearer and clearer evidence it doesn’t work in solid tumors. If not what’s the dream?

  6. prije 20 sati

    nice move into close not matched by , assume shortcovering. bounced 22% after falling early, Up volume was 2.5-1.

  7. prije 23 sata

    major moves -6.82 % change recently

  8. prije 23 sata
    Odgovor korisnicima

    For targeting anti-CD47 in cancer could be an ideal partner connecting EGFR expression to macrophages / NK-cells

    2 proslijeđena tweeta 9 korisnika označava da im se sviđa
  9. 4. velj

    +16.49% weak today against this tape. Holding short

  10. 4. velj

    underwhelming data for anti-CD47 magrolimab + PD1 combo in solid tumor in ASCO-SITC abstract 0% ORR in 18 ovarian cancer patients

    5 replies 20 proslijeđenih tweetova 46 korisnika označava da im se sviđa
  11. 3. velj

    CONCLUSION : M+A is a novel, well-tolerated combination treatment regimen with 1 observed PR in a ST pt and a 56% SD rate in OC pts. Tumor shrinkage was noted in the only OC pt with tumor cell expression of PD-L1 which warrants further evaluation in PD-L1+ OC pts

    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  12. 3. velj

    Sun et al. expression correlates with progression, immunotherapy with anti-CD47 mAb enhanced MM killing by macrophages in PBMCs mediated by an enhanced phagocytosis.

    7 proslijeđenih tweetova 10 korisnika označava da im se sviđa
  13. 3. velj
    Odgovor korisniku/ci

    Agree 100% the next runner like is . Could start as early as today if posts decent data in their ovarian abstract AH.

    1 reply 1 proslijeđeni tweet 1 korisnik označava da mu se sviđa
  14. 3. velj

    , and are the top gainers for the day.

  15. 3. velj

    ovarian abstract should b available AH today @ 5pm ET. Stock is moving like we should expect a good abstract. Positive data in solids changes everything. 🙏🤞

    2 proslijeđena tweeta 7 korisnika označava da im se sviđa
  16. 3. velj

    $10 Rule couple months back positioned for another leg higher. Still long.

    1 reply 1 korisnik označava da mu se sviđa
  17. 2. velj

    Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus # via

  18. 2. velj

    CD47-Blocking Antibodies and Atherosclerosis . Decreasing senescent platelets would be a huge advantage for treating arteriosclerosis...advantage

    1 reply 1 proslijeđeni tweet 8 korisnika označava da im se sviđa
  19. 31. sij

    - Key events next week - healthcare

    1 proslijeđeni tweet
  20. 30. sij

    So there’s at a $1.9B market cap and at $116M. Very similar tech but from what I remember has some advantages, interesting op if true

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.